In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Midatech Pharma PLC

www.midatechpharma.com

Latest From Midatech Pharma PLC

Bookmark
  • Interviews

New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’

By Sten Stovall

Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.

Commercial Companies
Bookmark
  • Analysis

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

By Joseph Haas and Jo Shorthouse

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial
Bookmark
  • News

Embattled Midatech Receives Lifeline From China To Save Cancer Candidate

By Jo Shorthouse

A Chinese billionaire has invested in UK biotech Midatech and signed a licensing deal for an as yet unapproved carcinoid cancer drug, sending it much-needed backing just days after the company said it did not have enough cash to get it to the second half of the year.

Cancer Financing
Bookmark
  • News

UK's Midatech Makes Desperate Cash Call

By Kevin Grogan

The Oxford-based biotech needs more money and fast to fund development of MTD201, which it believes offers a number of competitive advantages over Novartis blockbuster Sandostatin LAR.

Financing Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Midatech Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Midatech Pharma PLC
  • Senior Management
  • Craig Cook, MD, CEO
    Nick Robbins-Cherry, CFO
    Steve Damment, PhD, Head, R&D
    Rob Rainey, Head, Corp. Dev.
  • Contact Info
  • Midatech Pharma PLC
    Phone: 1235 841 575
    65 Innovation Dr.
    Milton Pk
    Abingdon, OX14 4RQ
    UK
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By